Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Passage Bio Inc's Business Segments
Passage Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Genetic Medicines Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Genetic Medicines Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Genetic Medicines Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Genetic Medicines Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Genetic Medicines Segment | - | - |
Description of Passage Bio Inc
Passage Bio Inc. is a clinical-stage genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system (CNS) disorders. The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
Passage Bio aims to address the underlying genetic causes of CNS disorders by utilizing a proprietary adeno-associated virus (AAV) gene therapy platform. AAVs are non-pathogenic viruses that have been engineered to deliver therapeutic genes to specific cells in the body. This targeted approach allows for the precise correction of the genetic defects causing the disorders.
The company's pipeline focuses on rare monogenic diseases such as infantile GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases), frontotemporal dementia, and Krabbe disease. These disorders are caused by mutations in single genes and result in severe neurological impairments.
Passage Bio has a collaborative research agreement with the University of Pennsylvania's Gene Therapy Program, which provides the company access to groundbreaking gene therapy research. Through this collaboration, Passage Bio is able to leverage the expertise of leading scientists and clinicians in the field of genetic medicine.
The company's lead product candidate is PBGM01, a gene therapy for infantile GM1 gangliosidosis. This disease is characterized by rapid neurodegeneration and severely hampers the development and functionality of affected infants. PBGM01 aims to restore the defective enzyme responsible for the breakdown of GM1 ganglioside, a lipid that accumulates in the cells of affected individuals.
Passage Bio's potential therapies undergo rigorous preclinical studies and extensive clinical trials to demonstrate their safety and efficacy. The company's approach involves utilizing sophisticated manufacturing and characterization processes to ensure consistent and reliable production of their AAV-based gene therapies.
In addition to its gene therapy programs, Passage Bio is actively engaged in research collaborations with academic institutions and industry partners to advance the understanding of genetic diseases and explore the potential of new therapeutic modalities.
As of the time of this writing, Passage Bio is a publicly traded company on the NASDAQ stock exchange under the ticker symbol PASG. The company continues to strive towards its mission of developing life-changing treatments for patients with rare CNS disorders, aiming to improve their quality of life and offer hope to individuals and families affected by these devastating conditions.
Passage Bio aims to address the underlying genetic causes of CNS disorders by utilizing a proprietary adeno-associated virus (AAV) gene therapy platform. AAVs are non-pathogenic viruses that have been engineered to deliver therapeutic genes to specific cells in the body. This targeted approach allows for the precise correction of the genetic defects causing the disorders.
The company's pipeline focuses on rare monogenic diseases such as infantile GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases), frontotemporal dementia, and Krabbe disease. These disorders are caused by mutations in single genes and result in severe neurological impairments.
Passage Bio has a collaborative research agreement with the University of Pennsylvania's Gene Therapy Program, which provides the company access to groundbreaking gene therapy research. Through this collaboration, Passage Bio is able to leverage the expertise of leading scientists and clinicians in the field of genetic medicine.
The company's lead product candidate is PBGM01, a gene therapy for infantile GM1 gangliosidosis. This disease is characterized by rapid neurodegeneration and severely hampers the development and functionality of affected infants. PBGM01 aims to restore the defective enzyme responsible for the breakdown of GM1 ganglioside, a lipid that accumulates in the cells of affected individuals.
Passage Bio's potential therapies undergo rigorous preclinical studies and extensive clinical trials to demonstrate their safety and efficacy. The company's approach involves utilizing sophisticated manufacturing and characterization processes to ensure consistent and reliable production of their AAV-based gene therapies.
In addition to its gene therapy programs, Passage Bio is actively engaged in research collaborations with academic institutions and industry partners to advance the understanding of genetic diseases and explore the potential of new therapeutic modalities.
As of the time of this writing, Passage Bio is a publicly traded company on the NASDAQ stock exchange under the ticker symbol PASG. The company continues to strive towards its mission of developing life-changing treatments for patients with rare CNS disorders, aiming to improve their quality of life and offer hope to individuals and families affected by these devastating conditions.
Passage Bio Inc. is a biotechnology company that is primarily focused on developing and commercializing transformative gene therapies tailored for the treatment of rare and neuropathic disorders. Their operations can be broken down into several key segments, products, and services, which collectively aim to address significant unmet medical needs in the field of gene therapy.
Segments
1. Research and Development (R&D):
- Passage Bio allocates a substantial portion of its resources towards R&D, engaging in extensive studies and experimental protocols. This segment is crucial for identifying and characterizing potential new gene therapy candidates, as well as gaining a deeper understanding of the underlying molecular mechanisms of various diseases. They conduct preclinical research, leveraging innovative technologies to explore gene editing and delivery methods.
- The R&D efforts also encompass collaborations with academic institutions and other research organizations, aimed at enhancing their methodological approaches and expanding their scientific capabilities.
Products
1. Candidate Therapies:
- Passage Bio is actively focused on a rich pipeline of gene therapy candidates targeting specific rare and neuropathic diseases.
- PBGM01: This is the lead product candidate aimed at treating GM1 gangliosidosis, a severe genetic disorder that affects the brain and nervous system. PBGM01 utilizes an adeno-associated viral (AAV) vector designed to deliver a therapeutic gene directly to the central nervous system, where it is expected to mitigate the progression of the disease.
- PBFT02: Another significant candidate in their pipeline for frontotemporal dementia (FTD). This therapy is in development to offer a novel approach to manage a disorder that impacts behavior and language, utilizing gene therapy mechanisms to potentially alter disease pathways and improve patient outcomes.
Services
1. Clinical Trials:
- Passage Bio undertakes comprehensive clinical trials to assess the safety and efficacy of their gene therapy candidates. These trials are integral to their development strategy and include various phases designed to evaluate different aspects of their therapies.
- The company provides essential services related to patient recruitment, ensuring diverse participant availability, data collection methodologies, ongoing monitoring of trial subjects, and maintaining rigorous regulatory compliance throughout the process. By conducting these trials, Passage Bio aims to gather critical evidence of their products’ effectiveness and pave the way for regulatory approval.
2. Patient Support:
- In addition to therapeutic development, Passage Bio emphasizes the importance of patient support services. Recognizing the complexities faced by patients with rare disorders, the company offers an array of supportive services designed to assist both patients and their families.
- This includes access programs that may provide therapies on an early or compassionate use basis, educational resources about their conditions and available treatments, and community engagement initiatives that foster a supportive environment for patients navigating their health journeys.
3. Partnerships:
- To enhance their research and development efforts, Passage Bio actively seeks partnerships with other biotechnology companies, academic researchers, and healthcare organizations. These collaborations aim to expedite the development of their gene therapies through shared expertise, joint research initiatives, and leveraging complementary technologies.
- Partnership engagements also extend to manufacturing capabilities, ensuring that the production of therapeutic products meets the required standards for quality and compliance. By creating a robust network of collaborations, Passage Bio works to streamline the pathway to market for their gene therapy products.
Summary
In essence, Passage Bio Inc. offers a multi-faceted approach to the development of gene therapies aimed at rare and neuropathic disorders. Through a well-defined focus on research and development, a promising pipeline of therapeutic candidates, and a dedication to providing patient-centric services, they are positioned to make significant contributions to the field of biotechnology, ultimately striving to improve the quality of life for individuals affected by these challenging conditions. Their holistic approach, which encompasses clinical trials, patient support, and strategic partnerships, reflects a commitment to innovation and excellence within the biopharmaceutical landscape.
Segments
1. Research and Development (R&D):
- Passage Bio allocates a substantial portion of its resources towards R&D, engaging in extensive studies and experimental protocols. This segment is crucial for identifying and characterizing potential new gene therapy candidates, as well as gaining a deeper understanding of the underlying molecular mechanisms of various diseases. They conduct preclinical research, leveraging innovative technologies to explore gene editing and delivery methods.
- The R&D efforts also encompass collaborations with academic institutions and other research organizations, aimed at enhancing their methodological approaches and expanding their scientific capabilities.
Products
1. Candidate Therapies:
- Passage Bio is actively focused on a rich pipeline of gene therapy candidates targeting specific rare and neuropathic diseases.
- PBGM01: This is the lead product candidate aimed at treating GM1 gangliosidosis, a severe genetic disorder that affects the brain and nervous system. PBGM01 utilizes an adeno-associated viral (AAV) vector designed to deliver a therapeutic gene directly to the central nervous system, where it is expected to mitigate the progression of the disease.
- PBFT02: Another significant candidate in their pipeline for frontotemporal dementia (FTD). This therapy is in development to offer a novel approach to manage a disorder that impacts behavior and language, utilizing gene therapy mechanisms to potentially alter disease pathways and improve patient outcomes.
Services
1. Clinical Trials:
- Passage Bio undertakes comprehensive clinical trials to assess the safety and efficacy of their gene therapy candidates. These trials are integral to their development strategy and include various phases designed to evaluate different aspects of their therapies.
- The company provides essential services related to patient recruitment, ensuring diverse participant availability, data collection methodologies, ongoing monitoring of trial subjects, and maintaining rigorous regulatory compliance throughout the process. By conducting these trials, Passage Bio aims to gather critical evidence of their products’ effectiveness and pave the way for regulatory approval.
2. Patient Support:
- In addition to therapeutic development, Passage Bio emphasizes the importance of patient support services. Recognizing the complexities faced by patients with rare disorders, the company offers an array of supportive services designed to assist both patients and their families.
- This includes access programs that may provide therapies on an early or compassionate use basis, educational resources about their conditions and available treatments, and community engagement initiatives that foster a supportive environment for patients navigating their health journeys.
3. Partnerships:
- To enhance their research and development efforts, Passage Bio actively seeks partnerships with other biotechnology companies, academic researchers, and healthcare organizations. These collaborations aim to expedite the development of their gene therapies through shared expertise, joint research initiatives, and leveraging complementary technologies.
- Partnership engagements also extend to manufacturing capabilities, ensuring that the production of therapeutic products meets the required standards for quality and compliance. By creating a robust network of collaborations, Passage Bio works to streamline the pathway to market for their gene therapy products.
Summary
In essence, Passage Bio Inc. offers a multi-faceted approach to the development of gene therapies aimed at rare and neuropathic disorders. Through a well-defined focus on research and development, a promising pipeline of therapeutic candidates, and a dedication to providing patient-centric services, they are positioned to make significant contributions to the field of biotechnology, ultimately striving to improve the quality of life for individuals affected by these challenging conditions. Their holistic approach, which encompasses clinical trials, patient support, and strategic partnerships, reflects a commitment to innovation and excellence within the biopharmaceutical landscape.